The intraocular pressure-lowering properties of intravenous paracetamol

Henning van den Heever, David Meyer Division of Ophthalmology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa Aim: The aim of this paper was to investigate the intraocular pressure (IOP)-changing properties of a single standard dose of intravenous (IV) pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	van den Heever H, Meyer D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Paracetamol Intraocular Pressure Endocannabinoid Ocular Hypotensive Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/40f7f5960aa34b0bb4869fb12df60b4e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:40f7f5960aa34b0bb4869fb12df60b4e
record_format	dspace
spelling	oai:doaj.org-article:40f7f5960aa34b0bb4869fb12df60b4e2021-12-02T02:40:33ZThe intraocular pressure-lowering properties of intravenous paracetamol1177-5483https://doaj.org/article/40f7f5960aa34b0bb4869fb12df60b4e2016-07-01T00:00:00Zhttps://www.dovepress.com/the-intraocular-pressure-lowering-properties-of-intravenous-paracetamo-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Henning van den Heever, David Meyer Division of Ophthalmology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa Aim: The aim of this paper was to investigate the intraocular pressure (IOP)-changing properties of a single standard dose of intravenous (IV) paracetamol and compare it to that of topical timolol, oral acetazolamide, and no treatment. Methods: A prospective, randomized, investigator-blind, parallel-group study was conducted in 73 eyes of 52 subjects. Subjects received a single dose of IV paracetamol (1 g), oral acetazolamide (250 mg), topical timolol (0.5%, one drop), or no treatment. Baseline IOP was measured, and the measurement was repeated at 1, 2, 4, and 6 hours after treatment. Results: Paracetamol reduced IOP from baseline by -10.8% (95% confidence interval [CI]: -4.9% to -16.8%, P=0.146) at 1 hour, -13.3% (95% CI: -8.3% to -18.4%, P=0.045) at 2 hours, -11.8% (95% CI: -5.5% to -18.4%, P=1.000) at 4 hours, and -23.9% (95% CI: -17.8% to -30.1%, P=0.006) at 6 hours after treatment. In the no-treatment group, the change was -2.9% (95% CI: +1.0% to -6.7%, P= referent) at 1 hour, -2.1% (95% CI: +2.9% to -7.2%, P= referent) at 2 hours, -7.6% (95% CI: -3.9% to -11.2%, P= referent) at 4 hours, and -6.9% (95% CI: -3.6% to -10.2%, P= referent) at 6 hours. Acetazolamide reduced IOP by -18.8% (95% CI: -12.7% to -24.8%, P=0.000) at 1 hour, -26.2% (95% CI: -18.2% to -34.2%, P=0.001) at 2 hours, -24.6% (95% CI: -16.9% to -32.3%, P=0.000) after 4 hours, and -26.9% (95% CI: -19.6% to -34.3%, P=0.000) 6 hours after treatment. Timolol reduced IOP by -31.2% (95% CI: -26.7% to -35.7%, P=0.000) at 1 hour, -27.7% (95% CI: -20.7% to -34.8%, P=0.000) at 2 hours, -28.7% (95% CI: -21.1% to -36.2%, P=0.000) at 4 hours, and -21.3% (95% CI: -13.4% to -30.0%, P=0.030) at 6 hours after treatment. The average change in IOP for the no-treatment group was -4.8% (95% CI: -2.6% to -6.9%, P= referent). It was -15.7% (95% CI: -9.3% to -22.1%, P=0.021) for paracetamol, -23.1% (95% CI: -16.4% to -29.8%, P=0.000) for acetazolamide, and -25.3% for the timolol group (95% CI: -19.4% to -31.2%, P=0.000). The maximal change in IOP for the no-treatment group was -9.2% (95% CI: -3.2% to -15.3%, P= referent). It was -25.9% (95% CI: -16.6% to -35.2%, P=0.009) for paracetamol, -33.8% (95% CI: -25.5% to -42.1%, P=0.000) for acetazolamide, and -36.8% (95% CI: -31.0% to -42.5%, P=0.000) for the timolol group. Conclusion: Intravenously administered paracetamol shows IOP-lowering properties over the first 6 hours after administration. Clinicians performing IOP measurements in patients who have received IV paracetamol in the preceding 6 hours should interpret these measurements with caution. Further studies are needed to investigate the IOP-changing properties of paracetamol. Keywords: AM404, anandamide, endocannabinoid, ocular hypotensivevan den Heever HMeyer DDove Medical PressarticleParacetamol Intraocular Pressure Endocannabinoid Ocular HypotensiveOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 1283-1289 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Paracetamol Intraocular Pressure Endocannabinoid Ocular Hypotensive Ophthalmology RE1-994
spellingShingle	Paracetamol Intraocular Pressure Endocannabinoid Ocular Hypotensive Ophthalmology RE1-994 van den Heever H Meyer D The intraocular pressure-lowering properties of intravenous paracetamol
description	Henning van den Heever, David Meyer Division of Ophthalmology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa Aim: The aim of this paper was to investigate the intraocular pressure (IOP)-changing properties of a single standard dose of intravenous (IV) paracetamol and compare it to that of topical timolol, oral acetazolamide, and no treatment. Methods: A prospective, randomized, investigator-blind, parallel-group study was conducted in 73 eyes of 52 subjects. Subjects received a single dose of IV paracetamol (1 g), oral acetazolamide (250 mg), topical timolol (0.5%, one drop), or no treatment. Baseline IOP was measured, and the measurement was repeated at 1, 2, 4, and 6 hours after treatment. Results: Paracetamol reduced IOP from baseline by -10.8% (95% confidence interval [CI]: -4.9% to -16.8%, P=0.146) at 1 hour, -13.3% (95% CI: -8.3% to -18.4%, P=0.045) at 2 hours, -11.8% (95% CI: -5.5% to -18.4%, P=1.000) at 4 hours, and -23.9% (95% CI: -17.8% to -30.1%, P=0.006) at 6 hours after treatment. In the no-treatment group, the change was -2.9% (95% CI: +1.0% to -6.7%, P= referent) at 1 hour, -2.1% (95% CI: +2.9% to -7.2%, P= referent) at 2 hours, -7.6% (95% CI: -3.9% to -11.2%, P= referent) at 4 hours, and -6.9% (95% CI: -3.6% to -10.2%, P= referent) at 6 hours. Acetazolamide reduced IOP by -18.8% (95% CI: -12.7% to -24.8%, P=0.000) at 1 hour, -26.2% (95% CI: -18.2% to -34.2%, P=0.001) at 2 hours, -24.6% (95% CI: -16.9% to -32.3%, P=0.000) after 4 hours, and -26.9% (95% CI: -19.6% to -34.3%, P=0.000) 6 hours after treatment. Timolol reduced IOP by -31.2% (95% CI: -26.7% to -35.7%, P=0.000) at 1 hour, -27.7% (95% CI: -20.7% to -34.8%, P=0.000) at 2 hours, -28.7% (95% CI: -21.1% to -36.2%, P=0.000) at 4 hours, and -21.3% (95% CI: -13.4% to -30.0%, P=0.030) at 6 hours after treatment. The average change in IOP for the no-treatment group was -4.8% (95% CI: -2.6% to -6.9%, P= referent). It was -15.7% (95% CI: -9.3% to -22.1%, P=0.021) for paracetamol, -23.1% (95% CI: -16.4% to -29.8%, P=0.000) for acetazolamide, and -25.3% for the timolol group (95% CI: -19.4% to -31.2%, P=0.000). The maximal change in IOP for the no-treatment group was -9.2% (95% CI: -3.2% to -15.3%, P= referent). It was -25.9% (95% CI: -16.6% to -35.2%, P=0.009) for paracetamol, -33.8% (95% CI: -25.5% to -42.1%, P=0.000) for acetazolamide, and -36.8% (95% CI: -31.0% to -42.5%, P=0.000) for the timolol group. Conclusion: Intravenously administered paracetamol shows IOP-lowering properties over the first 6 hours after administration. Clinicians performing IOP measurements in patients who have received IV paracetamol in the preceding 6 hours should interpret these measurements with caution. Further studies are needed to investigate the IOP-changing properties of paracetamol. Keywords: AM404, anandamide, endocannabinoid, ocular hypotensive
format	article
author	van den Heever H Meyer D
author_facet	van den Heever H Meyer D
author_sort	van den Heever H
title	The intraocular pressure-lowering properties of intravenous paracetamol
title_short	The intraocular pressure-lowering properties of intravenous paracetamol
title_full	The intraocular pressure-lowering properties of intravenous paracetamol
title_fullStr	The intraocular pressure-lowering properties of intravenous paracetamol
title_full_unstemmed	The intraocular pressure-lowering properties of intravenous paracetamol
title_sort	intraocular pressure-lowering properties of intravenous paracetamol
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/40f7f5960aa34b0bb4869fb12df60b4e
work_keys_str_mv	AT vandenheeverh theintraocularpressureloweringpropertiesofintravenousparacetamol AT meyerd theintraocularpressureloweringpropertiesofintravenousparacetamol AT vandenheeverh intraocularpressureloweringpropertiesofintravenousparacetamol AT meyerd intraocularpressureloweringpropertiesofintravenousparacetamol
_version_	1718402279735820288

The intraocular pressure-lowering properties of intravenous paracetamol

Ejemplares similares